Beneficial modulation of the gut microbiota is an attractive therapeutic approach to improve the efficacy of vaccine-induced immunity. In this study, mice were supplemented with the prebiotic milk oligosaccharide 2’-fucosyllactose (2’FL) as well as a complex mixture of immune modulatory prebiotic short-chain galacto-oligosaccharides and long-chain fructo-oligosaccharides (scGOS/lcFOS) from different stages in early life. Adult mice were vaccinated with trivalent influenza vaccine (TIV) and both development of the gut microbiota and antibody-mediated vaccine responses were followed over time. Within the control group, female mice demonstrated a larger antibody response to TIV vaccination than male mice, which was accompanied by enhanced cytokine production by splenocytes and a higher percentage of plasma cells in skin draining lymph nodes. In addition, the prebiotic diet improved vaccine-specific antibody responses in male mice. Introduction of prebiotics into the diet modulated the gut microbiota composition and at the genus level several bacterial groups showed a significant interaction effect which potentially contributed to the immunological effects observed. This study provides insight in the effect of scGOS/lcFOS/2’FL in influenza vaccination antibody production.
RESEARCH ARTICLE
Prebiotic oligosaccharides in early life alter gut microbiome development in male mice while supporting influenza vaccination responses
L.W.J. van den Elsen Related information
1Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.
, S. Tims Related information1Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.
, A.M. Jones Related information1Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.
, A. Stewart Related information1Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.
, B. Stahl Related information2Danone Nutricia Research, Departments of Immunology/Microbiology/Human Milk Research, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands.
, J. Garssen Related information2Danone Nutricia Research, Departments of Immunology/Microbiology/Human Milk Research, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands.
3Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands.
, J. Knol Related information3Utrecht University, Faculty of Science, Department of Pharmaceutical Sciences, Division of Pharmacology, Universiteitsweg 99, 3584 CG Utrecht, the Netherlands.
2Danone Nutricia Research, Departments of Immunology/Microbiology/Human Milk Research, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands.
4Wageningen University & Research, 6708 PB Wageningen, the Netherlands.
, E.E. Forbes-Blom Related information4Wageningen University & Research, 6708 PB Wageningen, the Netherlands.
1Malaghan Institute of Medical Research, Gate 7 Victoria University, Kelburn Parade, Wellington 6012, New Zealand.
#these authors contributed equally to this work
, B. van’t Land Related information#these authors contributed equally to this work
2Danone Nutricia Research, Departments of Immunology/Microbiology/Human Milk Research, Uppsalalaan 12, 3584 CT Utrecht, the Netherlands.
5University Medical Center Utrecht, The Wilhelmina Children’s Hospital, Laboratory of Translational Immunology, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
#these authors contributed equally to this work
*Corresponding author: b. vantland@umcutrecht. nl
5University Medical Center Utrecht, The Wilhelmina Children’s Hospital, Laboratory of Translational Immunology, Heidelberglaan 100, 3584 CX Utrecht, the Netherlands.
#these authors contributed equally to this work
*Corresponding author: b.
Beneficial Microbes: 10
(3)- Pages: 279 - 291
Published Online: February 18, 2019
Abstract
Keywords: HMOS, gender, TIV, antibody, microbiota
2022 Journal Impact Factor
5.4
source: Journal Impact Factor 2023™ from Clarivate™
Institutional Offers
For institutional orders, please contact [email protected].
-
A.A. Hibberd, C.C. Yde, M.L. Ziegler, A.H. Honoré, M.T. Saarinen, S. Lahtinen, B. Stahl, H.M. Jensen and L.K. Stenman
-
E.E. Blaak, E.E. Canfora, S. Theis, G. Frost, A.K. Groen, G. Mithieux, A. Nauta, K. Scott, B. Stahl, J. van Harsselaar, R. van Tol, E.E. Vaughan and K. Verbeke
-
K. Venema, J. Verhoeven, C. Beckman and D. Keller
-
E. Arvidsson Nordström, C. Teixeira, C. Montelius, B. Jeppsson and N. Larsson
-
J.E. Haarhuis, A. Kardinaal and G.A.M. Kortman
-
E.E. Blaak, E.E. Canfora, S. Theis, G. Frost, A.K. Groen, G. Mithieux, A. Nauta, K. Scott, B. Stahl, J. van Harsselaar, R. van Tol, E.E. Vaughan and K. Verbeke
-
K. Lippert, L. Kedenko, L. Antonielli, I. Kedenko, C. Gemeier, M. Leitner, A. Kautzky-Willer, B. Paulweber and E. Hackl
-
K. Tsilingiri and M. Rescigno
-
M. Ozen and E.C. Dinleyici
-
Y. Kobayashi, T. Kuhara, M. Oki and J.-Z. Xiao